Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE.
ALOXI vs ONDANSETRON HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, inhibiting emetic reflex.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
8 mg orally or intravenously every 8 hours; maximum 24 mg/day. For prevention of chemotherapy-induced nausea and vomiting, 8 mg intravenously or 24 mg orally 30 minutes before chemotherapy.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 3-6 hours in adults, 4-6 hours in elderly, and 5-7 hours in severe hepatic impairment (Child-Pugh Class C).
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Renal: 5% unchanged; hepatic metabolism accounts for >95% of elimination; metabolites excreted in urine (44-60%) and feces (25-33%).
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."